ArticleCancers2021
Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2
Registry-linked trialAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01521676 (Research of Predictive Clinical and Biological Parameters in Breast Cancer), which is not on this map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research of Predictive Clinical and Biological Parameters in Breast Cancer
Who cites it
10 citing papers in PubMed.
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- CyTOF as a suitable tool for stratification and monitoring of cancer patients.Journal of translational medicine · 2025Review
- Application of mass cytometry in the immune microenvironment of breast cancer.Medical oncology (Northwood, London, England) · 2025Review
- FromFrontiers in immunology · 2025Review
- The evolution of immune profiling: will there be a role for nanoparticles?Nanoscale horizons · 2024Review
- Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer.Nature communications · 2024Article
- Analysis of the Effector Functions of Vδ2 γδ T Cells and NK Cells against Cholangiocarcinoma Cells.Cells · 2024Article
- Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives.Frontiers in immunology · 2024Review
- Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy.Frontiers in oncology · 2023Review
- γδ T cell exhaustion: Opportunities for intervention.Journal of leukocyte biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Stéphane FattoriTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Laurent GorvelTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Samuel GranjeaudSystems Biology Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Philippe RochigneuxTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.ORCID 0000-0001-7932-0530
Marie-Sarah RouvièreTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Amira Ben AmaraTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Nicolas BoucheritTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Magali PaulTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Marie Mélanie DauplatDepartment of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
Jeanne Thomassin-PianaDepartment of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
Maria Paciencia-GrosDepartment of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
Morgan AveninDepartment of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
Jihane PakradouniDepartment of Clinical Research and Innovations, Institut Paoli-Calmettes, 13009 Marseille, France.
Julien BarrouDepartment of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.ORCID 0000-0001-5774-5028
Emmanuelle Charafe-JauffretDepartment of Pathology, Institut Paoli-Calmettes, 13009 Marseille, France.
Gilles HouvenaeghelDepartment of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
Eric LambaudieDepartment of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
François BertucciDepartment of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
Anthony GoncalvesDepartment of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.ORCID 0000-0001-7570-7439
Carole TarpinDepartment of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
Jacques A NunèsTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.ORCID 0000-0003-4865-0400
Raynier DevillierTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.ORCID 0000-0002-4045-8310
Anne-Sophie ChretienTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.
Daniel OliveTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.ORCID 0000-0003-1299-4113
Funding
Cancéropôle PACA AML_CyTOF 2016Cancéropôle PACA K_CyTOF 2014FRM DEQ20140329534FRM DEQ20180339209INCa 2012-064/2019-038SIRIC Marseille INCa-DGOS-INSERM 6038
Abstract
The rationale for therapeutic targeting of Vδ2
Indexed as
between-group analysisbreast cancersimmune monitoringliquid biopsymass cytometryγδ T cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01521676ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.